{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "TWD", "exchange": "TWO", "shortName": "PHARMAESSENTIA CORP", "longName": "PharmaEssentia Corporation", "messageBoardId": "finmb_60427403", "exchangeTimezoneName": "Asia/Taipei", "exchangeTimezoneShortName": "CST", "gmtOffSetMilliseconds": 28800000, "market": "tw_market", "esgPopulated": false, "regularMarketChangePercent": -2.7576196, "regularMarketPrice": 335.0, "marketState": "POSTPOST", "firstTradeDateMilliseconds": 1394499600000, "priceHint": 2, "epsTrailingTwelveMonths": -4.58, "epsForward": 9.38, "epsCurrentYear": -2.98, "priceEpsCurrentYear": -112.41611, "sharesOutstanding": 338456000, "bookValue": 41.198, "fiftyDayAverage": 425.11, "fiftyDayAverageChange": -90.109985, "fiftyDayAverageChangePercent": -0.21196865, "twoHundredDayAverage": 493.65802, "twoHundredDayAverageChange": -158.65802, "twoHundredDayAverageChangePercent": -0.32139257, "marketCap": 114863792128, "forwardPE": 35.714287, "priceToBook": 8.131462, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "1.0 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -9.5, "regularMarketTime": 1684128619, "regularMarketDayHigh": 351.0, "regularMarketDayRange": "333.0 - 351.0", "regularMarketDayLow": 333.0, "regularMarketVolume": 3440966, "regularMarketPreviousClose": 344.5, "bid": 334.5, "ask": 335.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Taipei Exchange", "financialCurrency": "TWD", "regularMarketOpen": 344.5, "averageDailyVolume3Month": 2078071, "averageDailyVolume10Day": 3129600, "fiftyTwoWeekLowChange": 2.0, "fiftyTwoWeekLowChangePercent": 0.006006006, "fiftyTwoWeekRange": "333.0 - 622.0", "fiftyTwoWeekHighChange": -287.0, "fiftyTwoWeekHighChangePercent": -0.46141478, "fiftyTwoWeekLow": 333.0, "fiftyTwoWeekHigh": 622.0, "earningsTimestamp": 1683802740, "earningsTimestampStart": 1691665140, "earningsTimestampEnd": 1692014400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "6446.TWO"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "No. 3, Park Street", "address2": "2nd & 13th Floors Nangang District", "city": "Taipei", "zip": "115", "country": "Taiwan", "phone": "886 2 2655 7688", "fax": "886 2 2655 7626", "website": "https://www.pharmaessentia.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, primary myelofibrosis, polycythemia vera, and essential thrombocythemia. The company licensed to develop Oraxol for the treatment of breast, gastric, gastro-esophageal, and esophageal cancer; and KX01 for the treatment of psoriasis. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Ching-Leou  Teng Ph.D.", "title": "Chairman & Chief Pharmaceutical Officer", "fiscalYear": 2021, "totalPay": {"raw": 8492000, "fmt": "8.49M", "longFmt": "8,492,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ko-Chung  Lin Ph.D.", "title": "Founder, CEO, Chief Strategy Officer & Director", "fiscalYear": 2021, "totalPay": {"raw": 9389000, "fmt": "9.39M", "longFmt": "9,389,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chan-Kou  Hwang", "title": "Pres, GM & Director", "fiscalYear": 2021, "totalPay": {"raw": 8492000, "fmt": "8.49M", "longFmt": "8,492,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Snow  Chang", "title": "Accounting Mang. & Sr. Mang. of Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Samuel  Lin", "title": "VP and Head of Bus. Operations & Strategy", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lih-Ling  Lin Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Rachel  Lipsitz", "title": "VP and Head of Corp. Communications & Advocacy", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Roddy  Mcilwain", "title": "Sr. VP and Head of Sales & Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anjana  Pursnani", "title": "Sr. VP & Head of People", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Albert  Qin M.D., Ph.D.", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}